They also reported an analogue activity of lorlatinib in NSCLC patients with intracranial lesions bearing ALK, or c-ros oncogene 1 (ROS1)-positive rearrangements/mutations [53]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.